AudioCure Pharma — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

AudioCure Pharma is a private, clinical-stage biotech based in Berlin, Germany, founded in 2015 (operational since 2012) to develop first-in-class pharmacotherapies for hearing disorders. The company's core asset is AC102, a novel small molecule currently in Phase II for idiopathic sudden sensorineural hearing loss (ISSNHL), with a completed Phase I trial in 2021. Targeting a massive market with no approved drugs, AudioCure's strategy is to move beyond symptomatic treatment to directly protect and restore inner ear cells and their connections. The company is led by a seasoned CEO and its founder, a clinician-scientist, and is backed by strategic investors and academic partners like Charité University.

OtologyNeurology

Technology Platform

Novel small molecule platform focused on neuroprotection and neuroregeneration of inner ear cells (e.g., hair cells, synapses, neurons) to address the root cause of sensorineural hearing loss and tinnitus.

Opportunities

The complete lack of approved pharmacotherapies for sensorineural hearing loss and tinnitus presents a massive, untapped multi-billion dollar global market.

A successful first-in-class drug like AC102 could establish a new standard of care in acute settings (e.g., sudden hearing loss) and potentially expand into large chronic indications, commanding significant pricing power and transforming patient outcomes.

Risk Factors

The key risk is clinical failure of AC102 in the ongoing Phase II trial, which would invalidate the core technology.

The company also faces financial dependency on external funding, regulatory uncertainty for a novel therapy, and potential future competition from other entities developing hearing loss treatments.

Competitive Landscape

The competitive landscape for drug treatments of sensorineural hearing loss is nascent but evolving. A handful of other biotech companies are exploring gene therapies, regenerative biologics, and other neuroprotective small molecules. However, there are currently no approved drugs, making AudioCure a pioneer. Its primary competition is the entrenched standard of care (corticosteroids, devices) and the high barrier of clinical proof required to change medical practice.

More companies in Small Molecule Drugs →More companies in Germany →